Drug intelligence / Profile preview

RTX-V002

Development stage: Unknown
Lead developer: Renhaim
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RTX-V002 is an investigational therapeutic vaccine developed using mRNA technology by Renhaim. It is being researched as both a disease-modifying osteoarthritis drug (DMOAD) and as an idiotype cancer vaccine. The drug is in the discovery phase and has not yet entered clinical trials. Its primary therapeutic areas are neoplasms (cancers) and osteoarthritis, with ongoing research into its potential to modify disease progression in osteoarthritis and to serve as a personalized cancer immunotherapy through mRNA-based vaccination[2][7].

Brand names: RTX-V002RTX-V-002RTX-V 002
Other names: RTX-V002RTX-V-002RTX-V 002

Beyond the preview

Go deeper on RTX-V002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RTX-V002.

Explore the full profile